Ngui J S, Chen Q, Shou M, Wang R W, Stearns R A, Baillie T A, Tang W
Department of Drug Metabolism, Merck Research Laboratories, Rahway, New Jersey 07065, USA.
Drug Metab Dispos. 2001 Jun;29(6):877-86.
It has been demonstrated that the activity of cytochrome P450 (CYP)3A4 in certain cases is stimulated by quinidine (positive heterotropic cooperativity). We report herein that the 4'- and 10-hydroxylation of S- and R-warfarin are enhanced in human liver microsomal incubations containing quinidine. These reactions were catalyzed by CYP3A4, based on data derived from immunoinhibitory studies, with 4'-hydroxylation being preferentially associated with S-warfarin and 10-hydroxylation with R-warfarin. The 4'-hydroxylation of S-warfarin and 10-hydroxylation of R-warfarin increased with increasing quinidine concentrations and maximized at ~3- and 5-fold the values of controls, respectively. Stimulatory effects of quinidine also were observed with recombinant CYP3A4, suggesting that increases in warfarin metabolism were due to quinidine-mediated enhancement of CYP3A4 activity. This positive cooperativity of CYP3A4 was characterized by a 2.5-fold increase in V(max) for the 4'-hydroxylation of S-warfarin and a 5-fold increase in V(max) for the 10-hydroxylation of R-warfarin, with little change in K(m) values. Conversely, V(max) for the 3-hydroxylation of quinidine was not influenced by the presence of warfarin. These results are consistent with previous findings suggesting the existence of more than one binding site in CYP3A4 through which interactions may occur between substrate and effector at the active site of the enzyme. Such interactions were subsequently illustrated by a kinetic model containing two binding domains, and a good regression fit was obtained for the experimental data. Finally, stimulation of warfarin metabolism by quinidine was investigated in suspensions of human hepatocytes, and increases in the formation of 4'- and 10-hydroxywarfarin again were observed in the presence of quinidine, indicating that this type of drug-drug interaction occurs in intact cells.
已证明在某些情况下,奎尼丁可刺激细胞色素P450(CYP)3A4的活性(正异源协同作用)。我们在此报告,在含有奎尼丁的人肝微粒体孵育体系中,S-和R-华法林的4'-和10-羟基化作用增强。基于免疫抑制研究的数据,这些反应由CYP3A4催化,其中4'-羟基化作用优先与S-华法林相关,而10-羟基化作用与R-华法林相关。S-华法林的4'-羟基化作用和R-华法林的10-羟基化作用随奎尼丁浓度的增加而增加,分别在对照值的约3倍和5倍时达到最大值。在重组CYP3A4中也观察到奎尼丁的刺激作用,这表明华法林代谢的增加是由于奎尼丁介导的CYP3A4活性增强。CYP3A4的这种正协同作用的特征是,S-华法林4'-羟基化作用的V(max)增加2.5倍,R-华法林10-羟基化作用的V(max)增加5倍,而K(m)值变化不大。相反,奎尼丁3-羟基化作用的V(max)不受华法林存在的影响。这些结果与先前的发现一致,表明CYP3A4中存在多个结合位点,通过这些位点底物和效应物可能在酶的活性位点发生相互作用。随后通过包含两个结合域的动力学模型说明了这种相互作用,并对实验数据获得了良好的回归拟合。最后,在人肝细胞悬液中研究了奎尼丁对华法林代谢的刺激作用,在存在奎尼丁的情况下再次观察到4'-和10-羟基华法林形成的增加,表明这种类型的药物-药物相互作用发生在完整细胞中。